Furthermore, mutations in PTPN itself can result in opposite functions, as previously described, where PTPN3 inhibits the progression of cholangiocarcinoma by suppressing the AKT signaling pathway, whereas mutated PTPN3 promotes the oncogenic properties of cholangiocarcinoma (130, 131). Here, AKT1 is linked to cholangiocarcinoma.